126410-47-7

Usage

Uses

Used in Organic Synthesis:
-<2-<4-(benzyloxy)phenyl>-1-oxiranylethyl>carbamic acid 1,1-dimethylethyl ester is used as an intermediate in organic synthesis for the creation of various complex molecules. Its unique structure allows for selective reactions and functional group manipulations, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Drug Development:
In the pharmaceutical industry, -<2-<4-(benzyloxy)phenyl>-1-oxiranylethyl>carbamic acid 1,1-dimethylethyl ester is used as a key building block in the development of new drugs. Its specific stereochemistry and functional groups can be exploited to design molecules with desired biological activities, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Research:
-<2-<4-(benzyloxy)phenyl>-1-oxiranylethyl>carbamic acid 1,1-dimethylethyl ester is also utilized as a research tool in chemical laboratories. Its unique structure provides opportunities for studying various aspects of chemistry, such as reaction mechanisms, stereoselectivity, and the influence of functional groups on reactivity. -<2-<4-(benzyloxy)phenyl>-1-oxiranylethyl>carbamic acid 1,1-dimethylethyl ester can contribute to the advancement of knowledge in organic chemistry and related fields.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 152438-62-5 (S)-N-[3-Chloro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]carbamic acid 1,1-dimethylethyl ester 
• 114645-18-0 [1-(4-benzyloxy-benzyl)-3-diazo-2-oxo-propyl]-carbamic acid tert-butyl ester 
• 1026977-99-0 C₂₆H₃₃NO₇ 
• 2130-96-3 O-benzyl-N-tert-butoxycarbonyl-L-tyrosine 
• 1059189-63-7 [(S)-1-(4-Benzyloxy-benzyl)-3-chloro-2-hydroxy-propyl]-carbamic acid tert-butyl ester 
• 126410-46-6 3(S)-<(tert-butyloxycarbonyl)amino>-4-<4-(benzyloxy)phenyl>-1-butene 

Downstream Products

• 162539-58-4 [(S)-1-(4-Benzyloxy-benzyl)-3-((S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenyl-butylamino)-2-hydroxy-propyl]-carbamic acid tert-butyl ester 
• 162536-85-8 (2S,3S)-N-tert-butoxycarbonyl-3-amino-1,2-epoxy-4-(4-hydroxyphenyl)butane 
• 1003869-72-4 t-butyl-(1S,2R)-1-(4-hydroxybenzyl)-2,3-epoxydo-propyl-carbamate 
• 313680-94-3 tert-butyl (1S,2R)-2-hydroxy-3-(isobutylamino)-1-{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]benzyl}propylcarbamate 
• 126438-29-7 3(R)-<<4-(benzyloxy)phenyl>methyl>-5(S)-<1'-(S)-<(tert-butyloxycarbonyl)amino>-2-<4-(benzyloxy)phenyl>ethyl>dihydrofuran-2(3H)-one 
• 140468-54-8 3(S)-<<4-(benzyloxy)phenyl>methyl>-5(S)-<1'-(S)-<(tert-butyloxycarbonyl)amino>-2-<4-(benzyloxy)phenyl>ethyl>dihydrofuran-2(3H)-one 
• 126410-51-3 3(R)-(phenylmethyl)-5(S)-<1'-(S)-<(tert-butyloxycarbonyl)amino>-2-<4-(benzyloxy)phenyl>ethyl>dihydrofuran-2(3H)-one 
• 126410-51-3 3(S)-(phenylmethyl)-5(S)-<1'-(S)-<(tert-butyloxycarbonyl)amino>-2-<4-(benzyloxy)phenyl>ethyl>dihydrofuran-2(3H)-one 
• 138483-73-5 N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-<(tert-butyloxycarbonyl)amino>-4(S)-hydroxy-6-<4-<2-(4-morpholinyl)ethoxy>phenyl>-2(R)-<<4-<2-(4-morpholinyl)ethoxy>phenyl>methyl>hexanamide 
• 126410-54-6 N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-<(tert-butyloxycarbonyl)amino>-4(S)-hydroxy-6-<4-(benzyloxy)phenyl>-2(R)-<<4-(benzyloxy)phenyl>methyl>hexanamide 
• 126410-53-5 3-carbethoxy-3-<<4-(benzyloxy)phenyl>methyl>-5(S)-<1'-(S)-<(tert-butyloxycarbonyl)amino>-2-<4-(benzyloxy)phenyl>ethyl>dihydrofuran-2(3H)-one 
• 126438-30-0 5(S)-<(tert-butyloxycarbonyl)amino>-4(S)-<(tert-butyldimethylsilyl)oxy>-6-<4-(benzyloxy)phenyl>-2(R)-<<4-(benzyloxy)phenyl>methyl>hexanoic acid 
• 165453-12-3 5(S)-(Boc-Amino)-4(S)-hydroxy-6-(p-benzyloxyphenyl)-2(R)-[(p-benzyloxyphenyl)methyl]hexanoic acid 
• 126410-13-7 N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-<(tert-butyloxycarbonyl)amino>-4(S)-hydroxy-6-(4-hydroxyphenyl)-2(R)-<(4-hydroxyphenyl)methyl>hexanamide 

Relevant academic research and scientific papers

Inhibitors of aspartyl protease

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Aminodiol HIV protease inhibitors. Synthesis and structure - Activity relationships of P1/P1′ compounds: Correlation between lipophilicity and cytotoxicity

A series of novel aminodiol inhibitors of HIV protease based on the lead compound 1 with structural modifications at P1′ were synthesized in order to reduce the cytotoxicity of 1. We have observed a high degree of correlation between the lipophilicity and the cytotoxicity of this series of inhibitors. It was found that appropriate substitution at the para position of the P1′ phenyl group of 1 resulted in the identification of equipotent (both against the enzyme and in cell culture) compounds (101, 10m, 10n, and 15c) which possess significantly decreased cytotoxicity.

Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1'phenyl substituents: X-ray crystal structure assisted design

By tethering of a polar hydrophilic group to the P1 or P1' substituent of a Phe-based hydroxyethylene isostere, the antiviral potency of a series of HIV protease inhibitors was improved. The optimum enhancement of anti-HIV activity was observed with the 4-morpholinylethoxy substituent. The substituent effect is consistent with a model derived from inhibitor docked in the crystal structure of the native enzyme. An X-ray crystal structure of the inhibited enzyme determined to 2.25 A verifies the modeling predictions.